자폐장애 아동의 약물효과 평정을 위한 이상행동 체크리스트 예비연구

다국어 초록 (Multilingual Abstract)

Objectives：We assessed the availability of Aberrant Behavior Checklist (ABC) for the evaluation of the pharmacological effect in autistic disorder.
Methods：A retrospective review of the medical records of 27 children with autistic disorder, who visited the department of child and adolescent psychiatry of Kyungpook National University Hospital, from October 2011 to February 2013, was conducted. After treatment with risperidone, changes in the severity and improvement of symptoms were measured using ABC at the baseline, 2nd visit and 3rd visit, respectively.
Results：The mean daily dose of risperidone increased from 0.66±0.27mg (baseline, initial dose) to 1.02±0.50mg, 2nd visit, and 1.19±0.50mg, 3rd visit. According to ABC, irritability, lethargy, hyperactivity, and inappropriate speech subscale scores decreased significantly from the baseline to 2nd visit. Irritability and Hyperactivity subscale scores decreased significantly from the 2nd to 3rd visit. All subscales and total scores of ABC decreased significantly from the baseline to 3rd visit.
Conclusion：The results of this study suggest that ABC can be used as an efficient tool to measure the symptoms of autistic disorder and to evaluate the medication effect on continuous treatment.

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 결론
• References

참고문헌 (Reference)

1 유희정, "전반적 발달장애의 한국형 치료 권고안 : 진단 및 평가" 대한소아청소년 정신의학회 18 (18): 97-108, 2007

2 조인희, "전반적 발달장애의 한국형 치료 권고안 : 약물치료" 대한소아청소년 정신의학회 18 (18): 109-116, 2007

3 Karabekiroglu K, "Validity of the aberrant behavior checklist in a clinical sample of toddlers" 40 : 99-110, 2009

4 Heykants J, "The pharmacokinetics of risperidone in humans: a summary" 55 (55): 13-17, 1994

5 Shea S, "Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders" 114 : e634-e641, 2004

6 Canitano R, "Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents" 4 : 723-730, 2008

7 McCracken JT, "Risperidone in children with autism and serious behavioral problems" 347 : 314-321, 2002

8 Pandina GJ, "Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial" 37 : 367-373, 2007

9 Aman MG, "Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions" 92 : 237-240, 1987

10 Freund LS, "Rating problem behaviors in outpatients with mental retardation: use of the Aberrant Behavior Checklist" 12 : 435-451, 1991

11 Scahill L, "Psychopharmacology, In Handbook of autism and pervasive developmental disorders" Wiley 1102-1122, 2005

12 Aman MG, "Psychometric characteristics of the aberrant behavior checklist" 89 : 492-502, 1985

13 Dean AJ, "Predictors of medication adherence in children receiving psychotropic medication" 47 : 350-355, 2011

14 Volkmar F, "Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues" 38 (38): 32S-54S, 1999

15 King BH, "Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders" 30 : 439-445, 2000

16 Myers SM, "Management of children with autism spectrum disorders" 120 : 1162-1182, 2007

17 Hollander E, "Impact of recent findings on study design of future autism clinical trials" 9 : 49-56, 2004

18 Marshburn EC, "Factor validity and norms for the aberrant behavior checklist in a community sample of children with mental retardation" 22 : 357-373, 1992

19 Brinkley J, "Factor analysis of the aberrant behavior checklist in individuals with autism spectrum disorders" 37 : 1949-1959, 2007

20 Glascoe FP, "Early detection of developmental and behavioral problems" 21 : 272-279, 2000

21 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" American Psychiatric Press 69-84, 2000

22 Hillman JL, "Childhood Autism" 49-, 2007

23 Scahill L, "Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trials" 43 : 739-746, 2013

24 Nazeer A, "Autism spectrum disorders: clinical features and diagnosis" 59 : 19-25, 2012

25 Chavez B, "Atypical antipsychotics in children with pervasive developmental disorders" 9 : 249-266, 2007

26 Seida JC, "Antipsychotics for children and young adults: a comparative effectiveness review" 129 : e771-e784, 2012